Second Generation Phenylthiazole Antibiotics for Treatment of MRSA
- Summary
- Researchers at Purdue University have developed second generation Phenylthiazole antibiotics with enhanced pharmacokinetic properties. After synthesis, tuning, and proper treatment of the substances, one of the compounds showed significant improvement in in-vitro anti-MRSA potency. The rapid elimination of bacterial cells was achieved. This series has improved pharmacokinetic properties compared to the first generation with a better safety profile.
- Technology Benefits
- Improved pharmacokinetic propertiesRapid elimination of bacterial cellsSignificant improvement in in-vitro anti-MRSA potency
- Technology Application
- MRSA treatmentTreatment of other 'superbugs'Antibiotic development
- Detailed Technology Description
- Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- None
- *Abstract
-
None
- *Background
- The most common 'superbug' found in hospitals is Methicillin-Resistant Staphylococcus Aureus (MRSA). In the 1940s, 95 percent of staphylococcus aureus could be controlled by penicillin, but that is now down to 10 percent (DailyMail.com). The CDC estimates that there are over 80,000 invasive MRSA infections annually, resulting in over 11,000 deaths. Even with the continuous development of new antibiotics to use against MRSA, bacterial resistance continues to grow. Phenylthiazoles have been examined as a new class of antibiotics, but its potential is hampered by poor pharmacokinetic profiles.
- *IP Issue Date
- None
- *IP Type
- Provisional
- *Stage of Development
- Concept validated through theory, simulation, or models
- *Web Links
- Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipMark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
